These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26033268)

  • 1. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
    Deardorff WJ; Feen E; Grossberg GT
    Drugs Aging; 2015 Jul; 32(7):537-47. PubMed ID: 26033268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cholinesterase inhibitor treatment of Alzheimer's disease.
    Johannsen P
    CNS Drugs; 2004; 18(12):757-68. PubMed ID: 15377166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
    Seltzer B
    J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.
    Buckley JS; Salpeter SR
    Drugs Aging; 2015 Jun; 32(6):453-67. PubMed ID: 25941104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.